BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy BMS-986253 plus nivolumab/ipilimumab failed to improve responses or PFS in advanced melanoma after progression on or after a checkpoint inhibitor.

BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy #melsm #ESMOImmuno24 #oncology www.onclive.com/view/bms-986...

T-DXd Plus Pembrolizumab Elicits Responses in IO-Naive HER2-Expressing or -Mutant NSCLC Trastuzumab deruxtecan plus pembrolizumab showed early efficacy in patients with IO-naive, HER2-expressing or -mutant non–small cell lung cancer.

T-DXd Plus Pembrolizumab Elicits Responses in IO-Naive HER2-Expressing or -Mutant NSCLC #ESMOImmuno24 #lcsm #oncology www.onclive.com/view/t-dxd-p...

@ESMO

What an amazing #ESMOImmuno24! 🌟

We were excited to share the results on the Early PD-L1 and TILs Dynamics of the Neo-CheckRay trial.

Laurence Buisseret @laubdh.bsky.social wrapped it up with an inspiring talk on Investigator-Initiated Trials!

🙏 Looking forward to next year!

#ESMOImmuno24
Proffered paper🔥

Ph III CM73L: Nivo+cCRT➡️consol Nivo/Ipi v Nivo v cCRT➡️Durva @solangepeters.bsky.social

- no PFS/OS benefit
- g3+TRAE 57%, 54%, 49%
- concerning pneumonitis signal

Concurrent RT+IO - going going gone
@oncoalert.bsky.social #LCSM #Medsky #Oncsky

#ESMOImmuno24
Proffered paper🔥

Gut microbiome in Ph III NIPPON trial (N/I/chemo v Pembro/chemo 1L) #JCOG

- Fusicatenibacter, Butyricicoccus = ⬆️ OS (esp with N+I: HR 0.56, 0.52) & ⬇️severe irAEs
- Blautia = ⬆️OS
- Prevotella species = ⬇️OS with N+I

@oncoalert.bsky.social #MedSky #OncSky #LCSM

Very proud of my 'partner-in-crime' 🙌 for showcasing our #MANIFESTuk consortium publicly for the first time at #ESMOImmuno24. Go @zaydtippu.bsky.social - you are a star! 🌟

Excited to get going with delivery in 2025!

@crick.ac.uk
@icrlondon.bsky.social
@cruk-mi.bsky.social
@mcrcnews.bsky.social

📚 In conjunction with #ESMOImmuno24, we had our annual #ESMO #IOTECH Editorial Board meeting today - delighted to see many more academics now here 🦋.

🎯 EiC: @haanenjohn.bsky.social

Section Editors:
@michalbassani.bsky.social (NeoAg/TILs)
@danielathommen.bsky.social (Biomarkers/novel IO targets)...

Oncologist in the making 👇
Kudos to our Elena Speziale from @CampusBioMedicoUniversity 🎯
If you're at #ESMOImmuno24 check out her work on the potential dose-dependent detrimental effect of PPIs in patients treated with #IO
Preliminary findings sparking reflections with clinical implications 🤔

When @marianabrandao0.bsky.social makes us travel from Geneva #ESMOImmuno24 to Tomorrowland and the Smurf Village throught a brillant discussion of 3 mini orals about treatment strategies for NSCLC patients. Thank you!

Excellent discussion by @marianabrandao0.bsky.social on treatment of patients with #NSCLC #ESMOImmuno24 Insightful perspectives on recent advances!

Delighted to share the MANIFEST platform at #ESMOImmuno24 led by Samra Turajlic

Builds on themes of
👨‍💻 Sample, assay & data harmonisation
➡️For generation of multi-modal/composite biomarkers

🚨Job opportunities across the platform!

👇
manifest-io.org.uk

Privileged to be here on behalf of the consortium 🧬 🏥 💊!

Come and say 👋🏾 at Poster 40P!

👨🏾‍💻Additional info at
manifest-io.org.uk

#ESMOImmuno24

Congratulations to all #YoungOncologists - recipients of the #ESMOImmuno24 ESMO Merit Travel Grant 🏆!

📣 Special shout out to ZAYD 🙌 @zaydtippu.bsky.social - who will be presenting our work:
"MANIFEST: A Multiomic Profiling Platform for Immuno-Oncology Biomarker Discovery"

Go say hi - Poster: 40P!

Gutted not to be Geneva 🇨🇭 for #ESMOImmuno24 in person this year 🥹.

If you are presenting your work at #ESMOImmuno24, and potentially looking for a home for your research work, please consider submitting to our ESMO IOTECH journal:
🔗 esmoiotech.org

🎬 Fantastic start to #ESMOImmuno24 with ESMO-SITC primer. Highlighting challenges of IO biomarker discovery:

🔴 Heterogeneity in data, samples and assay types
🧬 Need for cross-study harmonisation & tailored composite biomarkers
💊 Neoadj. trials & PDTF’s offer opportunities for biomarker discovery!

#ESMOImmuno24: 🚨 Last Chance to Save on Registration 🚨
Exciting times ahead! Late-breaking abstract authors-titles are now online!
👉 Head to the programme to see the science you can look forward to and register today! Hope to see you there!
🔗https://ow.ly/QvNu50U483r